Core Insights - The beauty and personal care industry is experiencing significant development opportunities, with companies expanding internationally and making key advancements in innovative drug research [1] - Huolong Securities maintains a "recommended" rating for the beauty and personal care industry, highlighting the overall shift towards high-quality development [1] - Betaini Group's core brand, Winona, has successfully entered the Middle Eastern market, becoming the first Chinese functional skincare brand registered in Qatar, marking a new phase in the internationalization strategy of Chinese beauty brands [1] Group 1 - Winona opened its first offline store in Doha Mall, Qatar, representing a geographical expansion of the brand [1] - The opening ceremony was attended by prominent figures from the local healthcare and retail sectors, showcasing Winona's professional strength and international influence in the functional skincare field [2] - The successful entry into Qatar is attributed to Betaini's systematic compliance capabilities driven by independent research and development, as well as high-quality product formulations validated by extensive clinical trials [2] Group 2 - Betaini has stated that it is continuously improving its global channel network, with its brands operating locally in Southeast Asia, the Middle East, North America, and Europe [3] - The company emphasizes a cautious and pragmatic approach to international expansion, based on in-depth insights into different regional markets [3] - Future expansion plans will be disclosed through official company communications, ensuring transparency in the progress of specific country or region developments [3]

Core Viewpoint - The company expresses confidence in the long-term development of its brands, such as Winona and Pomei, in emerging markets like the Middle East, emphasizing a focus on market education and channel development [2]. Group 1: Market Performance - The brands Winona and Pomei are currently in the early stages of market introduction and localization in the Middle East [2]. - The company is committed to providing professional skincare solutions for sensitive skin to local consumers [2]. Group 2: Strategic Focus - The company is steadily advancing foundational work, including market education and channel construction, to support its overseas market initiatives [2]. - Investors are encouraged to monitor the company's upcoming periodic reports for specific market performance and financial data [2].

有投资者在互动平台向贝泰妮提问："请问我司薇诺娜和泊美等在中东上市以来表现怎么样？是否受当 地人喜欢？谢谢！" 针对上述提问，贝泰妮回应称："尊敬的投资者，您好！目前，薇诺娜等品牌在中东等新兴市场的业务 正处于市场引入与本土化运营的早期阶段。公司对海外市场的长期发展抱有充分耐心与信心，正稳步推 进包括市场教育、渠道建设在内的各项基础工作，致力于为当地消费者提供专业的敏感肌护肤解决方 案。关于具体的市场表现与财务数据，敬请关注公司后续发布的定期报告。感谢您的关注！" 声明：市场有风险，投资需谨慎。本文为AI基于第三方数据生成，仅供参考，不构成个人投资建议。 本文源自：市场资讯 作者：公告君 ...

Investment Rating - The report maintains a "Recommended" investment rating for the beauty and personal care industry [5][26]. Core Insights - Betaini Group's brand Winona has officially entered the Middle East market, expanding its overseas footprint by opening its first offline store in Doha Mall, Qatar, marking it as the first Chinese functional skincare brand registered in Qatar [5][24]. - The report highlights the global development strategy of companies in the medical beauty sector, emphasizing a transition from single product output to a systematic compliance layout and the value output of "Chinese solutions" [5][26]. - The report suggests focusing on companies with core raw material technology advantages and a full industry chain matrix, such as Marubi Biotechnology, Huaxi Biological, and Juzhi Biological [5][26]. Summary by Sections Recent Market Performance - From January 26 to January 30, 2026, the Shenwan Beauty and Personal Care Index decreased by 3.92% [13]. - The top five gainers in the sector included companies like Four Seasons Medicine and Yisi Health, while the biggest losers included Lafang Cosmetics and Shanghai Jahwa [13]. Industry News - Time安生物's siRNA weight loss drug targeting ALK7 has achieved global simultaneous submission for clinical trials, showcasing the company's global development strategy [18][19]. - The customs authority has introduced nine measures to support the development of the beauty industry, focusing on building Guangzhou as a global cosmetics manufacturing and consumption center [20]. Key Company Announcements - Baiya Co., Ltd. announced plans for share reduction by major shareholders, while Jeya Co., Ltd. plans to recognize asset impairment losses to reflect its financial status accurately [21][22]. Weekly Insights - The opening of Winona's store in Qatar is a significant step in the brand's globalization strategy, receiving recognition from local medical and retail sectors [24][25]. - The report emphasizes the importance of systematic compliance capabilities and clinical validation in the development of medical beauty enterprises [26]. Investment Recommendations - The report recommends focusing on companies with strong R&D capabilities and market positioning, such as Betaini and Aimeike, while also considering traditional brands that are actively transforming [26].

Core Viewpoint - The "Qihang·2025 Financial Summit" held in Beijing highlighted the importance of high-quality development in the financial sector, with Betaini winning the "Outstanding Marketing Case Award" for its innovative marketing practices [1][3]. Group 1: Award Significance - The "Jinzhi Award" aims to set benchmarks for high-quality development, guiding listed companies to focus on core businesses, continuous innovation, and social responsibility [3]. - The award evaluation covered over 8,000 companies across A-shares, Hong Kong stocks, and Chinese concept stocks, with nearly 200 companies recognized for their achievements [3]. Group 2: Betaini's Marketing Strategy - Betaini's award-winning marketing strategy is based on a "full-domain collaboration + value deepening" system, focusing on user needs and employing an OMO (Online-Merge-Offline) channel integration model [4]. - The company maintains a strong online presence on platforms like Tmall, Douyin, and JD, while also deepening its engagement in professional channels such as OTC pharmacies [4]. Group 3: Brand Development - Betaini has established a multi-brand collaborative development framework, with its core brand, Winona, leading the sensitive skin market and achieving significant recognition [4]. - The brand has consistently ranked in the top 10 of Tmall's beauty industry for nine consecutive years and has been recognized as a "Chinese Consumer Brand" by the Ministry of Industry and Information Technology [4]. Group 4: International Expansion - Betaini has successfully entered mainstream channels in Thailand and established brand recognition through platforms like TikTok, as well as in Hong Kong and Macau [5]. - The company is focused on integrating international technology brands while promoting Chinese skincare wisdom, aiming to transition from a leader in sensitive skin to a global skin health ecosystem [5].

Core Viewpoint - In the third quarter, Beitaini's net profit increased by 136.55%, indicating a potential turnaround from previous performance declines, although over 80% of revenue still relies on the main product, Winona, highlighting the need for further multi-brand development [1][2]. Financial Performance - In Q3, Beitaini reported revenue of 1.092 billion yuan, a year-on-year decline of 9.95%, while achieving a net profit of 25.22 million yuan, a year-on-year increase of 136.55% [2]. - For the first three quarters of 2025, Beitaini's revenue was 3.464 billion yuan, down 13.78% year-on-year, and net profit was 272 million yuan, down 34.45% year-on-year [2]. Brand Dependency - Winona brand generated revenue of 1.95 billion yuan in the first half of 2025, accounting for 82.17% of total company revenue, indicating that other brands contribute less than 20% [2]. - The heavy reliance on the main brand means that any slowdown in Winona's growth will directly impact Beitaini's overall performance [2]. Strategic Initiatives - Beitaini has recognized the importance of diversifying its business and has been actively seeking new growth through investments and acquisitions [2]. - In August, Beitaini announced a collaboration with a home radio frequency beauty device company, aiming to leverage advanced technology for quicker product development [2]. - In February, Beitaini acquired the Za and Bomei brands, previously owned by Shiseido, through a 51% stake in Yuejiang Investment [2].

Core Viewpoint - The significant increase in net profit for Betaini in Q3, up 136.55%, is seen as a potential turning point after several quarters of declining performance, although the sustainability of this growth remains uncertain due to reliance on cost-cutting measures [1][3]. Financial Performance - In Q3, Betaini reported revenue of 1.092 billion yuan, a year-on-year decline of 9.95%, while net profit reached 25.22 million yuan, marking a 136.55% increase [3]. - For the first three quarters of 2025, Betaini's operating costs were 889 million yuan, down 15.75% year-on-year, with a gross profit margin of approximately 74.33%, an increase of about 0.6 percentage points compared to the previous year [4]. - Despite the profit increase in Q3, overall performance shows significant pressure, with total revenue for the first three quarters of 2025 at 3.464 billion yuan, down 13.78%, and net profit at 272 million yuan, down 34.45% [4]. Brand Dependency - Betaini heavily relies on its main brand, Winona, which accounted for 82.17% of total revenue in the first half of 2025, indicating that other brands contribute less than 20% [7]. - Winona's revenue has shown a declining trend, with figures of 4.885 billion yuan, 5.192 billion yuan, and 4.909 billion yuan from 2022 to 2024, reflecting a slowdown in growth [7]. Strategic Initiatives - Betaini is actively seeking new growth points beyond its main brand through investments and acquisitions, including a partnership with the home-use RF beauty device brand Chupu and the acquisition of Shiseido's Za and Bomei brands [10]. - The company has increased its R&D investment, with 59 new patents obtained and R&D spending rising by 1.87% to 116 million yuan [11]. - Betaini aims to leverage its unique advantages in Chinese herbal ingredients and has established the "Yunnan Province Nest Zhi Mao Expert Workstation" to enhance product quality and technical standards [11].

Core Viewpoint - Betaini (300957.SZ), known as the "first stock in functional skincare," is intensifying its capital market strategy by investing in a new healthcare fund, aiming to diversify its business beyond its core beauty segment [1]. Investment Strategy - On October 13, Betaini announced plans to invest as a limited partner in the Wuxi Jinyu Maowu Medical Health Industry Investment Partnership (referred to as "Jinyu Fund"), with a total fund size of 1 billion CNY, focusing on consumer healthcare, pharmaceuticals, medical devices, and AI drug development [1][4]. - Betaini will contribute 50 million CNY, acquiring a 5% stake in the Jinyu Fund, which is part of a broader strategy to deepen cooperation with professional funds and enhance its presence in the health ecosystem [4]. Historical Investments - Over the past three years, Betaini has invested approximately 280 million CNY in various funds, including the Sequoia Fund and the San Zheng Fund, indicating a strategic shift towards capital investments to seek growth opportunities [3][9]. - The company has made several notable investments: 100 million CNY in the Sequoia Fund in June 2022, another 100 million CNY in the San Zheng Fund in April 2023, and 30 million CNY in the Jinguo Fund in October 2023 [5][9]. Financial Performance - Betaini's revenue growth has been declining, with reported revenues of 4.022 billion CNY in 2021, 5.014 billion CNY in 2022, 5.522 billion CNY in 2023, and 5.736 billion CNY in 2024, showing a decreasing growth rate from 52.57% to 3.87% [9]. - The net profit has also seen a downward trend, with figures of 863 million CNY in 2021, 1.051 billion CNY in 2022, 757 million CNY in 2023, and 503 million CNY in 2024, reflecting a significant decline in profitability [9]. Market Position and Competition - Betaini's core brand, Winona, has been a major revenue driver, contributing approximately 97% of total revenue in 2022, which decreased to around 86% in 2024, indicating a heavy reliance on a single brand [9]. - Other beauty brands, such as Proya and Marubi, are also increasing their capital investments to seek growth, highlighting a trend among leading beauty companies to diversify and enhance their market positions [10][11].

Core Viewpoint - Betaini, known as the "first stock in functional skincare," is intensifying its capital market strategy by establishing a new investment fund focused on healthcare and medical industries [1][3]. Investment Fund Overview - Betaini plans to invest as a limited partner in the Wuxi Jinyu Maowu Medical Health Industry Investment Partnership, with a total fund size of 1 billion yuan, focusing on consumer healthcare, pharmaceuticals, medical devices, and AI in drug development [1][3]. - The company will contribute 50 million yuan, acquiring a 5% stake in the fund, which has a 10-year partnership duration [2][3]. Historical Investment Activities - Over the past three years, Betaini has invested approximately 280 million yuan across various funds, including Sequoia Fund and San Zheng Fund, indicating a strategic shift towards capital investments beyond its core beauty business [2][4]. - Specific investments include 100 million yuan in Sequoia Fund in June 2022, 100 million yuan in San Zheng Fund in April 2023, and 30 million yuan in Jiangsu Jinguo New Materials Fund in October 2023 [2][4]. Financial Performance and Strategic Concerns - Betaini's revenue growth has been declining, with revenues of 4.022 billion yuan in 2021, 5.014 billion yuan in 2022, 5.522 billion yuan in 2023, and 5.736 billion yuan in 2024, showing a decreasing growth rate from 52.57% to 3.87% [6]. - The company's net profit has also decreased significantly, from 8.63 billion yuan in 2021 to 5.03 billion yuan in 2024, reflecting a trend of increasing revenue but declining profitability [6]. Brand Diversification Efforts - To mitigate reliance on its core brand Winona, which accounted for approximately 86% of total revenue in 2024, Betaini is expanding its brand portfolio by acquiring stakes in other brands and developing a multi-brand strategy [6][7]. - The company has invested 536 million yuan to acquire a 51% stake in Yuejiang (Guangzhou) Investment Co., aiming to integrate brands like Za and Pure&Mild into its offerings [6]. Industry Trends - Other major beauty brands, such as Proya and Marubi, are also increasing their capital investments to seek growth opportunities amid slowing sales, indicating a broader trend in the beauty industry towards capital market engagement [7][8].

Core Viewpoint - The performance commitments of the subsidiary acquired two years ago by Betaini are difficult to fulfill, compounded by a significant decline in performance over the past two years, putting the company's transformation under severe scrutiny [1] Group 1: Performance Issues - Betaini's acquisition of Yuedong Investment in 2023 for 536 million yuan aimed to integrate two major beauty brands, but the performance commitments have not been met, with completion rates of 86.2% and 34.47% for 2023 and 2024 respectively, and less than 30% for 2025 [3][4] - In 2024, Betaini reported its worst performance since going public, with revenue slightly increasing by 3.87% to 5.74 billion yuan, but net profit plummeting by 33.5% to 503 million yuan, and non-recurring net profit dropping by 61.1% to 240 million yuan [4] - Betaini has experienced a continuous decline in net profit for two consecutive years, with 2023 revenue at 5.522 billion yuan and net profit at 757 million yuan, a year-on-year decrease of 28.02% [5] Group 2: Market Position and Investor Sentiment - In the first half of 2025, Betaini continued its downward trend, achieving revenue of 2.372 billion yuan, a year-on-year decline of 15.43%, and net profit of 247 million yuan, down 49.01% [7] - Compared to peers like Proya, which saw a net profit increase of 270% from 2021 to 2024, Betaini's net profit decreased by nearly 42% during the same period [7] - Investors have expressed dissatisfaction, questioning management's ability to drive growth and suggesting a need for leadership changes [8] Group 3: Regulatory and Market Challenges - Betaini has faced multiple regulatory issues, including penalties for false advertising and recent orders for "rectification" from the Yunnan Provincial Drug Administration [8] - The company's stock price has significantly declined from a peak of 286.76 yuan per share at its IPO to 45.81 yuan as of October 9, 2025, representing an 84% drop and a market capitalization reduction of over 100 billion yuan [8] - Major shareholders are also exiting, with Sequoia Juye planning to reduce its stake by up to 2% of the total share capital, having already cashed out approximately 5.9 billion yuan in previous rounds [10]